|Positive WB detected in||HEK-293 cells, HEK-293|
|Positive IP detected in||HEK-293 cells|
|Positive IHC detected in||human colon cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||HepG2 cells|
|Western Blot (WB)||WB : 1:500-1:2000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:500-1:1000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:200-1:2000|
|Immunofluorescence (IF)||IF : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
66172-1-Ig targets MSH6 in WB, IP, IHC, IF,ELISA applications and shows reactivity with human samples.
|Host / Isotype||Mouse / IgG2a|
|Immunogen||MSH6 fusion protein Ag12645|
|Full Name||mutS homolog 6 (E. coli)|
|Calculated molecular weight||153 kDa|
|Observed molecular weight||160 kDa|
|GenBank accession number||BC004246|
|Gene ID (NCBI)||2956|
|Purification Method||Protein A purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
MSH6, also named as DNA mismatch repair protein Msh6 or GTMBP, is a 1360 amino acid protein, which contains one PWWP domain and belongs to the DNA mismatch repair MutS family. MSH6 localizes in the nucleus and is a component of the post-replicative DNA mismatch repair system. Msh2 and Msh6 form a protein complex required to repair mismatches generated during DNA replication.
|Product Specific Protocols|
|WB protocol for MSH6 antibody 66172-1-Ig||Download protocol|
|IHC protocol for MSH6 antibody 66172-1-Ig||Download protocol|
|IF protocol for MSH6 antibody 66172-1-Ig||Download protocol|
|IP protocol for MSH6 antibody 66172-1-Ig||Download protocol|
|Click here to view our Standard Protocols|
HDAC10 expression is associated with DNA mismatch repair gene and is a predictor of good prognosis in colon carcinoma.
J Surg Oncol
Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer.